文献速递前列腺癌

挽救性淋巴结清扫后PSA持续升高的定义及其对肿瘤结局的影响

Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy.
PubMed 文献 · Eur Urol Oncol · 2021-06-24

该多中心回顾性研究纳入579例根治性前列腺切除术后仅淋巴结复发行挽救性淋巴结清扫的患者,评估术后首次PSA与前列腺癌特异性死亡的关系。结果显示术后首次PSA≥0.3 ng/ml为最佳判别阈值,PSA持续升高独立预测不良预后;早期ADT仅对PSA持续升高或5年CSM预测风险>10%的患者有生存获益。

要点

  • 术后首次PSA≥0.3 ng/ml是预测CSM的最佳判别阈值(C指数0.757)。
  • PSA持续升高者临床复发、总死亡和CSM风险均显著增高。
  • 早期ADT仅对PSA持续升高或5年CSM风险>10%者有益。

核心结论

  • 挽救性淋巴结清扫后PSA持续升高独立预测不良预后,最佳判别阈值为PSA≥0.3 ng/ml。
  • 早期ADT仅对PSA持续升高或5年CSM预测风险>10%的患者有生存获益。

研究设计与样本

  • 多中心回顾性研究,纳入2000至2016年间11个高容量中心接受挽救性淋巴结清扫的579例患者。
  • 评估术后首次PSA与前列腺癌特异性死亡的线性关系,并将不同PSA持续定义纳入多变量模型预测CSM以确定最佳截断值。
  • 采用多变量回归模型分析PSA持续与肿瘤结局的关联,并按PSA持续状态和CSM估计风险检验早期ADT效果。

主要发现

  • 术后首次PSA与前列腺癌特异性生存概率呈负相关。
  • 以术后首次PSA≥0.3 ng/ml定义PSA持续提供最佳判别准确性(C指数0.757),331例(57%)患者符合该定义。
  • 幸存者中位随访48个月(四分位距27-74)。
  • 校正混杂因素后,PSA持续升高者临床复发风险(HR 1.61)、总死亡风险(HR 2.20)和CSM风险(HR 2.59)均更高(均p<0.001)。
  • 挽救性淋巴结清扫后早期ADT仅改善PSA持续患者的生存(HR 0.49;p=0.024);在纳入病理特征的多变量模型中,早期ADT仅对5年CSM预测风险>10%的患者有益。

关键数值与推荐

  • PSA持续定义为术后首次PSA≥0.3 ng/ml(C指数0.757)。
  • PSA持续升高者临床复发HR 1.61、总死亡HR 2.20、CSM HR 2.59(均p<0.001)。
  • PSA持续患者早期ADT的生存HR 0.49(p=0.024)。
  • 5年CSM预测风险>10%的患者可从早期ADT获益。

临床怎么用

  • 挽救性淋巴结清扫后应将术后首次PSA≥0.3 ng/ml作为PSA持续升高的定义用于风险分层。
  • 对PSA持续升高或5年CSM预测风险>10%的患者,可考虑早期ADT以改善生存。
  • 对无PSA持续且5年CSM风险≤10%的患者,早期ADT未见获益,应避免过度治疗。

局限性

  • 研究为回顾性设计,存在选择偏倚和未测量混杂的可能。
  • 早期ADT的获益需等待正在进行的前瞻性试验结果验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The optimal definition and prognostic significance of persistently elevated prostate-specific antigen (PSA) after salvage lymph node dissection (sLND) for node-only recurrent prostate cancer (PCa) remain unknown. OBJECTIVE: To assess the definition and clinical implications of persistently elevated PSA after sLND for node-only recurrent PCa after radical prostatectomy. DESIGN, SETTING, AND PARTICIPANTS: The study included 579 patients treated with sLND at 11 high-volume centers between 2000 and 2016. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: We assessed the linear relationship between the first PSA after sLND and death from PCa. Different definitions of PSA persistence were included in a multivariable model predicting cancer-specific mortality (CSM) after surgery to identify the best cutoff value. We investigated the association between PSA persistence and oncologic outcomes using multivariable regression models. Moreover, the effect of early androgen deprivation therapy (ADT) after sLND was tested according to PSA persistence status and estimated risk of CSM. RESULTS AND LIMITATIONS: We found an inverse relationship between the first PSA after sLND and the probability of cancer-specific survival. PSA persistence defined as first postoperative PSA ≥0.3 ng/ml provided the best discrimination accuracy (C index 0.757). According to this cutoff, 331 patients (57%) experienced PSA persistence. The median follow-up for survivors was 48 mo (interquartile range 27-74). After adjusting for confounders, men with persistently elevated PSA had higher risk of clinical recurrence (hazard ratio [HR] 1.61), overall mortality (HR 2.20), and CSM (HR 2.59; all p < 0.001) after sLND. Early ADT administration after sLND improved survival only for patients with PSA persistence after surgery (HR 0.49; p = 0.024). Similarly, when PSA persistence status was included in multivariable models accounting for pathologic features, early ADT use after sLND was beneficial only for patients with a predicted risk of CSM at 5 yr of >10%. CONCLUSIONS: PSA persistence after sLND independently predicts adverse prognosis, with the best discrimination accuracy for CSM provided by a definition of PSA ≥ 0.3 ng/ml. We showed that when stratifying patients by final pathology results and PSA persistence status, early ADT use after sLND was beneficial only for patients with PSA persistence or with a calculated 5-yr risk of CSM of >10%, which could be useful as we await results from ongoing prospective trials. PATIENT SUMMARY: We found that for patients with prostate cancer who had lymph nodes removed after their cancer recurred, persistently elevated prostate-specific antigen (PSA) levels predict poorer prognosis. We showed that a PSA level of ≥0.3 ng/ml provides the best accuracy in identifying patients with worse prognosis. This may help to improve risk stratification after lymph node removal and allow physicians to optimize treatment strategies after surgery.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Bravi CA, Droghetti M, Fossati N, et al. Definition and Impact on Oncologic Outcomes of Persistently Elevated Prostate-specific Antigen After Salvage Lymph Node Dissection for Node-only Recurrent Prostate Cancer After Radical Prostatectomy: Clinical Implications for Multimodal Therapy. Eur Urol Oncol. 2021. PMID: 34176768. doi:10.1016/j.euo.2021.06.003

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。